As soon as the face of the Canadian cannabis small business, the former Canopy Development chief executive Bruce Linton is producing a comeback in the business.

This week, Linton announced he is taking on new roles with two businesses in the sector, as properly as a directorial position at an Australian organization that functions with psychedelic-primarily based remedies for mental illnesses.

“You cannot remedy entrepreneurs,” he told Bloomberg, explaining that immediately after his ousting at Canopy Development, he spent the summer time searching for new possibilities.

In his pursuit of a “stable small business,” Linton chosen Florida-primarily based animal overall health and CBD corporation Much better Selection, exactly where he will assist with its CBD analysis efforts. The news of Linton joining Much better Selection sent the company’s stock soaring more than 20%.

Meanwhile, the co-founder of Canopy Development, who was fired more than the company’s disappointing earnings, will also serve as executive chairman at Massachusetts recreational marijuana dispensary Gage Cannabis Co.

Due to Linton signing a non-compete clause as component of his termination with Canopy, the businessman is not permitted to perform for Canadian cannabis businesses.

Gage not too long ago entered an exclusive partnership in Michigan with marijuana startup Cookies, a move which Linton told Bloomberg will position the corporation as a “dominant player” in the state.

Linton’s third new venture, Thoughts Medicine Inc., is oriented towards the therapeutic prospective of psychedelics like psilocybin.

According to the company’s web page, Thoughts Medicine “is looking for to establish secure and powerful psychedelic-assisted remedies for mental illness in Australia. As a registered charity (DGR-1 status), we are supporting clinical analysis and operating towards regulatory-authorized and proof-primarily based psychedelic-assisted therapies.”

In the United States, interest in this aspect of hallucinogenic drugs culminated in the launching of a new analysis center at John Hopkins Medicine not too long ago.

“The way I chosen the businesses was not how considerably equity they would give me. I turned down the most self-enriching delivers. Having said that, to be transparent, all firms offered me with generous equity exposure. With each and every firm and space, I sought to create a particular view of how we construct enterprise worth from the existing activities and limit disruption,” Linton mentioned in a various interview with Yahoo Finance on Tuesday.